Abstract
Functional imaging plays a complementary role to anatomical methods by providing metabolic and secretory information in endocrine organ disorders. Radiopharmaceuticals used for the evaluation of the thyroid, parathyroid, adrenal glands, and pancreatic neuroendocrine tumors reveal the functional status of lesions, thereby contributing to diagnosis, differential diagnosis, and treatment planning. Radionuclide imaging supports clinical management, particularly by demonstrating features such as multiglandular involvement, receptor expression, or hormone production capacity.
Keywords: Thyroid scintigraphy, [99mTc] sestamibi, [18F] FDG, MIBG, somatostatin receptor imaging, [68Ga] DOTATATE, adrenal disease, neuroendocrine tumors
References
Intenzo C, Miller J, Gulati A, Colarossi D, Parekh M. The role of nuclear medicine in benign thyroid disease. Semin Nucl Med. 2023; 53: 469-74.
Giovanella L, Avram AM, Iakovou I, Kwak J, Lawson SA, Lulaj E, et al. EANM practice guideline/SNMMI procedure standard for RAIU and thyroid scintigraphy. Eur J Nucl Med Mol Imaging. 2019; 46: 2514-25.
Baker CH, Morris JC. The sodium-iodide symporter. Curr Drug Targets Immune Endocr Metabol Disord. 2004; 4: 167-74.
Bongiovanni M, Paone G, Ceriani L, Pusztaszeri M. Cellular and molecular basis for thyroid cancer imaging in nuclear medicine. Clinical and Translational Imaging. 2013;1(3):149-61.
Bertagna F, Treglia G, Piccardo A, Giubbini R. Diagnostic and clinical significance of F-18-FDG-PET/CT thyroid incidentalomas. J Clin Endocrinol Metab. 2012; 97: 3866-75.
Familiar C, Merino S, Valhondo R, López C, Pérez X, De Los Monteros PE, et al. Prevalence and clinical significance in our setting of incidental uptake in the thyroid gland found on 18F-fluordeoxyglucose positron emission tomography-computed tomography (PET-CT). Endocrinol Diabetes Nutr (Engl Ed). 2023; 70: 171-8.
Grewal RK, Lubberink M, Pentlow KS, Larson SM. The role of iodine-124-positron emission tomography imaging in the management of patients with thyroid cancer. PET Clin. 2007l; 2: 313-20.
Rault E, Vandenberghe S, Van Holen R, De Beenhouwer J, Staelens S, Lemahieu I. Comparison of image quality of different iodine isotopes (I-123, I-124, and I-131). Cancer Biother Radiopharm. 2007; 22: 423-30.
Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NF, Cobin RH, et al. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA. 2004; 291: 228-38.
Saltiki K, Simeakis G, Karapanou O, Alevizaki M. MANAGEMENT OF ENDOCRINE DISEASE: Medullary thyroid cancer: from molecular biology and therapeutic pitfalls to future targeted treatment perspectives. Eur J Endocrinol. 2022; 187: R53-63.
Treglia G, Villani MF, Giordano A, Rufini V. Detection rate of recurrent medullary thyroid carcinoma using fluorine-18 fluorodeoxyglucose positron emission tomography: a meta-analysis. Endocrine. 2012; 42: 535-45.
Trimboli P, Mian C, Piccardo A, Treglia G. Diagnostic tests for medullary thyroid carcinoma: an umbrella review. Endocrine. 2023; 81: 183-93.
Jayasinghe R, Basnayake O, Jayarajah U, Seneviratne S. Management of medullary carcinoma of the thyroid: a review. J Int Med Res. 2022; 50: 3000605221110698.
Treglia G, Castaldi P, Villani MF, Perotti G, de Waure C, Filice A, et al. Comparison of 18F-DOPA, 18F-FDG and 68Ga-somatostatin analogue PET/CT in patients with recurrent medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2012; 39: 569-80.
Kaliszewski K, Ludwig M, Ludwig B, Mikuła A, Greniuk M, Rudnicki J. Update on the diagnosis and management of medullary thyroid cancer: what has changed in recent years? Cancers (Basel). 2022; 14: 3643.
Giovanella L, Treglia G, Iakovou I, Mihailovic J, Verburg FA, Luster M. EANM practice guideline for PET/CT imaging in medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2020; 47: 61-77.
Treglia G, Rufini V, Piccardo A, Imperiale A. Update on management of medullary thyroid carcinoma: focus on nuclear medicine. Semin Nucl Med. 2023; 53: 481-9.
Petranović Ovčariček P, Giovanella L, Carrió Gasset I, Hindié E, Huellner MW, Luster M, et al. The EANM practice guidelines for parathyroid imaging. Eur J Nucl Med Mol Imaging. 2021; 48: 2801-22.
Lalonde MN, Correia RD, Syktiotis GP, Schaefer N, Matter M, Prior JO. Parathyroid imaging. Semin Nucl Med. 2023; 53: 490-502.
Yeh MW, Ituarte PH, Zhou HC, Nishimoto S, Liu IL, Harari A, et al. Incidence and prevalence of primary hyperparathyroidism in a racially mixed population. J Clin Endocrinol Metab. 2013; 98: 1122-9.
Taterra D, Wong LM, Vikse J, Sanna B, Pękala P, Walocha J, et al. The prevalence and anatomy of parathyroid glands: a meta-analysis with implications for parathyroid surgery. Langenbecks Arch Surg. 2019; 404: 63-70.
Treglia G, Trimboli P, Huellner M, Giovanella L. Imaging in primary hyperparathyroidism: focus on the evidence-based diagnostic performance of different methods. Minerva Endocrinol. 2018; 43: 133-43.
Treglia G, Sadeghi R, Schalin-Jäntti C, Caldarella C, Ceriani L, Giovanella L, et al. Detection rate of (99m) Tc-MIBI single photon emission computed tomography (SPECT)/CT in preoperative planning for patients with primary hyperparathyroidism: a meta-analysis. Head Neck. 2016; 38: E2159-72.
Treglia G, Piccardo A, Imperiale A, Strobel K, Kaufmann PA, Prior JO, et al. Diagnostic performance of choline PET for detection of hyperfunctioning parathyroid glands in hyperparathyroidism: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2019; 46: 751-65.
Saha S, Vierkant RA, Johnson GB, Parvinian A, Wermers RA, Foster T, et al. C 11 choline PET/CT succeeds when conventional imaging for primary hyperparathyroidism fails. Surgery. 2023; 173: 117-23.
Weber T, Smaxwil C, Hermann M, Lenschow C, Lorenz K, Steinmüller T, et al. Results of 18 F-choline and 11 C-methionine positron emission tomography/computed tomography for the preoperative localization of hyperfunctional parathyroid glands in primary hyperparathyroidism. Surgery. 2025; 180: 109056.
Kuyumcu S, Denizmen D, Has-Simsek D, Poyanli A, Uzum AK, Buyukkaya F, et al. 68 Ga-Trivehexin PET/CT: a promising novel tracer for primary hyperparathyroidism. Eur J Nucl Med Mol Imaging. 2024; 51: 3912-23.
Werner RA, Schirbel A, Buck AK, Fassnacht M, Hahner S. Adrenal functional imaging. Presse Med. 2022; 51: 104114.
Avram AM, Fig LM, Gross MD. Adrenal gland scintigraphy. Semin Nucl Med. 2006; 36: 212-27.
Lenders JWM, Kerstens MN, Amar L, Prejbisz A, Robledo M, Taieb D, et al. Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension. J Hypertens. 2020; 38: 1443-56.
Ebbehoj A, Stochholm K, Jacobsen SF, Trolle C, Jepsen P, Robaczyk MG, et al. Incidence and clinical presentation of pheochromocytoma and sympathetic paraganglioma: a population-based study. J Clin Endocrinol Metab. 2021; 106: e2251-61.
Zhang X, Wakabayashi H, Hiromasa T, Kayano D, Kinuya S. Recent advances in radiopharmaceutical theranostics of pheochromocytoma and paraganglioma. Semin Nucl Med. 2023; 53: 503-16.
Taïeb D, Hicks RJ, Hindié E, Guillet BA, Avram A, Ghedini P, et al. European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging. 2019; 46: 2112-37.
Bomanji J, Levison DA, Flatman WD, Horne T, Bouloux PM, Ross G, et al. Uptake of iodine-123 MIBG by pheochromocytomas, paragangliomas, and neuroblastomas: a histopathological comparison. J Nucl Med. 1987; 28: 973-8.
Jaques S Jr, Tobes MC, Sisson JC. Sodium dependency of uptake of norepinephrine and m-iodobenzylguanidine into cultured human pheochromocytoma cells: evidence for uptake-one. Cancer Res. 1987; 47: 3920-8.
Berglund AS, Hulthén UL, Manhem P, Thorsson O, Wollmer P, Törnquist C. Metaiodobenzylguanidine (MIBG) scintigraphy and computed tomography (CT) in clinical practice. Primary and secondary evaluation for localization of phaeochromocytomas. J Intern Med. 2001; 249: 247-51.
Kan Y, Zhang S, Wang W, Liu J, Yang J, Wang Z. 68 Ga-somatostatin receptor analogs and 18 F-FDG PET/CT in the localization of metastatic pheochromocytomas and paragangliomas with germline mutations: a meta-analysis. Acta Radiol. 2018; 59: 1466-74.
Naji M, Zhao C, Welsh SJ, Meades R, Win Z, Ferrarese A, et al68Ga-DOTA-TATE PET vs. 123I-MIBG in identifying malignant neural crest tumours. Mol Imaging Biol. 2011; 13: 769-75.
Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015; 42: 328-54.
Cao L, Zhang D, Yang H, Xu W, Liu Y. 18 F-FDG-PET/CT-based machine learning model evaluates indeterminate adrenal nodules in patients with extra-adrenal malignancies. World J Surg Oncol. 2023; 21: 305.
Werner RA, Hartrampf PE, Schirbel A, Hahner S. Adrenal functional imaging - which marker for which indication? Curr Opin Urol. 2022; 32: 585-93.
Terzolo M, Bovio S, Pia A, Osella G, Borretta G, Angeli A, et al. Subclinical Cushing’s syndrome. Arq Bras Endocrinol Metabol. 2007; 51: 1272-9.
Hu J, Xu T, Shen H, Song Y, Yang J, Zhang A, et al. Accuracy of Gallium-68 pentixafor positron emission tomography-computed tomography for subtyping diagnosis of primary aldosteronism. JAMA Netw Open. 2023; 6: e2255609.
Fassnacht M, Arlt W, Bancos I, Dralle H, Newell-Price J, Sahdev A, et al. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2016; 175: G1-34.
Bozkurt MF, Virgolini I, Balogova S, Beheshti M, Rubello D, Decristoforo C, et al. Guideline for PET/CT imaging of neuroendocrine neoplasms with 68 Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18 F-DOPA. Eur J Nucl Med Mol Imaging. 2017; 44: 1588-1601.Erratum in: Eur J Nucl Med Mol Imaging. 2017; 44: 2150-1.
Seregni E, Chiti A, Bombardieri E. Radionuclide imaging of neuroendocrine tumours: biological basis and diagnostic results. Eur J Nucl Med. 1998; 25: 639-58.
Bombardieri E, Maccauro M, De Deckere E, Savelli G, Chiti A. Nuclear medicine imaging of neuroendocrine tumours. Ann Oncol. 2001; 12: S51-61.
Kayani I, Bomanji JB, Groves A, Conway G, Gacinovic S, Win T, et al. Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG. Cancer. 2008; 112: 2447-55.
Virgolini I, Ambrosini V, Bomanji JB, Baum RP, Fanti S, Gabriel M, et al. Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging. 2010; 37: 2004-10.
Prasad V, Ambrosini V, Hommann M, Hoersch D, Fanti S, Baum RP. Detection of unknown primary neuroendocrine tumours (CUP-NET) using (68)Ga-DOTA-NOC receptor PET/CT. Eur J Nucl Med Mol Imaging. 2010; 37: 67-77.
Kowalski J, Henze M, Schuhmacher J, Mäcke HR, Hofmann M, Haberkorn U. Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imaging Biol. 2003; 5: 42-8.
Öksüz MÖ, Winter L, Pfannenberg C, Reischl G, Müssig K, Bares R, et al. Peptide receptor radionuclide therapy of neuroendocrine tumors with (90)Y-DOTATOC: is treatment response predictable by pre-therapeutic uptake of (68)Ga-DOTATOC? Diagn Interv Imaging. 2014; 95: 289-300.
Binderup T, Knigge U, Loft A, Federspiel B, Kjaer A. 18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clin Cancer Res. 2010; 16: 978-85.
Werner RA, Weich A, Higuchi T, Schmid JS, Schirbel A, Lassmann M, et al. Imaging of chemokine receptor 4 expression in neuroendocrine tumors - a triple tracer comparative approach. Theranostics. 2017; 7: 1489-98.
Pfeifer A, Knigge U, Mortensen J, Oturai P, Berthelsen AK, Loft A, et al. Clinical PET of neuroendocrine tumors using 64Cu-DOTATATE: first-in-humans study. J Nucl Med. 2012; 53: 1207-15.
Hou G, Cheng X, Yang Y, Zhao D, Wang G, Zhao H, et al. Diagnostic performance and clinical impact of 18 F-AlF-NOTA-octreotide in a large cohort of patients with neuroendocrine neoplasms: A prospective single-center study. Theranostics. 2024; 14: 3213-20.
Long T, Yang N, Zhou M, Chen D, Li Y, Li J, et al. Clinical application of 18F-AlF-NOTA-octreotide PET/CT in combination with 18F-FDG PET/CT for imaging neuroendocrine neoplasms. Clin Nucl Med. 2019; 44: 452-8.
Christ E, Wild D, Forrer F, Brändle M, Sahli R, Clerici T, et al. Glucagon-like peptide-1 receptor imaging for localization of insulinomas. J Clin Endocrinol Metab. 2009; 94: 4398-405.
